Comment on CMS-2026-1256-0002

Summary: The Alliance for Patient Access, a national network of healthcare providers, supports the approval of the New Technology Add-On Payment for xanomeline and trospium chloride (Cobenfy). They argue that the drug provides a critical new mechanism of action for treating schizophrenia with fewer side effects—such as weight gain and tardive dyskinesia—compared to current standard-of-care antipsychotics.